See more : Electrameccanica Vehicles Corp. (SOLO) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex, Inc. (VERX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex, Inc., a leading company in the Software – Application industry within the Technology sector.
You may be interested
- Poseidon Nickel Limited (POS.AX) Income Statement Analysis – Financial Results
- Metalliance SA (MLETA.PA) Income Statement Analysis – Financial Results
- MLP Group S.A. (MLG.WA) Income Statement Analysis – Financial Results
- Gabriel Resources Ltd. (GBU.V) Income Statement Analysis – Financial Results
- BOA Acquisition Corp. (BOAS) Income Statement Analysis – Financial Results
Vertex, Inc. (VERX)
About Vertex, Inc.
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 572.39M | 491.62M | 425.55M | 374.67M | 321.50M | 272.40M |
| Cost of Revenue | 223.81M | 193.13M | 161.89M | 165.39M | 110.38M | 95.70M |
| Gross Profit | 348.58M | 298.49M | 263.66M | 209.28M | 211.12M | 176.71M |
| Gross Profit Ratio | 60.90% | 60.72% | 61.96% | 55.86% | 65.67% | 64.87% |
| Research & Development | 58.21M | 41.88M | 44.02M | 54.34M | 30.56M | 23.76M |
| General & Administrative | 145.94M | 121.65M | 107.01M | 149.06M | 71.01M | 58.95M |
| Selling & Marketing | 140.24M | 125.34M | 99.01M | 99.42M | 68.13M | 56.90M |
| SG&A | 286.17M | 246.99M | 206.01M | 248.48M | 139.14M | 115.85M |
| Other Expenses | 21.70M | 17.71M | 16.57M | 11.22M | 9.57M | 7.25M |
| Operating Expenses | 366.09M | 306.57M | 266.60M | 314.04M | 179.27M | 146.85M |
| Cost & Expenses | 579.81M | 499.71M | 428.49M | 479.42M | 289.65M | 242.54M |
| Interest Income | 0.00 | 1.68M | 984.00K | 1.72M | 1.08M | 526.00K |
| Interest Expense | 4.16M | 2.05M | 984.00K | 3.11M | 2.04M | 1.59M |
| Depreciation & Amortization | 74.46M | 76.28M | 56.73M | 32.22M | 25.19M | 24.90M |
| EBITDA | 56.95M | 53.07M | 41.84M | -72.54M | 58.13M | 22.07M |
| EBITDA Ratio | 9.95% | 10.80% | 9.83% | -19.36% | 18.08% | 20.10% |
| Operating Income | -7.42M | -8.08M | -2.94M | -104.76M | 31.86M | -2.83M |
| Operating Income Ratio | -1.30% | -1.64% | -0.69% | -27.96% | 9.91% | -1.04% |
| Total Other Income/Expenses | -14.25M | -2.05M | -984.00K | -3.11M | -953.00K | -34.41M |
| Income Before Tax | -21.67M | -10.13M | -3.93M | -107.87M | 30.90M | -4.43M |
| Income Before Tax Ratio | -3.79% | -2.06% | -0.92% | -28.79% | 9.61% | -1.63% |
| Income Tax Expense | -8.58M | 2.17M | -2.45M | -28.93M | 7.83M | 1.68M |
| Net Income | -13.09M | -12.30M | -1.48M | -78.94M | 23.08M | -6.11M |
| Net Income Ratio | -2.29% | -2.50% | -0.35% | -21.07% | 7.18% | -2.24% |
| EPS | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| EPS Diluted | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| Weighted Avg Shares Out | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
| Weighted Avg Shares Out (Dil) | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex's investigational therapies in...
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Its latest report of clinical data suggests it has a winner on its hands.
Vertex to Announce Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
KING OF PRUSSIA, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release third quarter 2024 financial results before the market opens on Wednesday, November...
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown great potential, and their recent M&A activity has...
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting...
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment process and high costs, alongside competition from Bluebird Bio, make the launch challenging....
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the...
New Strong Buy Stocks for October 7th
ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2024.
New Acquisitions Could Be Big For Vertex Stock As Shares Score Breakout
Corporate tax compliance software Vertex stock scores a breakout amid an array of acquisitions, as earnings growth begins to accelerate.
Best Growth Stocks to Buy for October 3rd
VERX, CARG, and UL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 3, 2024.
Source: https://incomestatements.info
Category: Stock Reports